by admin_63069 | Mar 31, 2025 | News You Can Use
Interpreting results in the context of evolving therapies, patient choice, and ongoing trials.
by admin_63069 | Mar 24, 2025 | News You Can Use
This study was specifically about the barriers and facilitators to first-line treatment intensification in metastatic castration-sensitive prostate cancer.
by admin_63069 | Mar 17, 2025 | News You Can Use
Patients with HRR-deficient metastatic castration-resistant prostate cancer experienced a 14-month gain in OS and a 38% lower death risk with Talzenna plus Xtandi.
by admin_63069 | Mar 10, 2025 | News You Can Use
Clearance of all visible prostate lesions at 6 months in five treated patients.
by admin_63069 | Mar 3, 2025 | News You Can Use
Advancing prostate cancer science through clinical trials and powerful data
by admin_63069 | Feb 24, 2025 | News You Can Use
Risk-benefit and individualized treatment
